An Expanded Access Program for AM0010 (Pegilodecakin) Subcutaneous Injection
| Registry | NCT03554434 |
|---|---|
| Status | No longer available |
| Study type | Expanded access |
| Sponsor | Eli Lilly and Company (Industry); collaborators: ARMO BioSciences |
| Conditions | Melanoma, Prostate Cancer, Ovarian Cancer, Renal Cell Carcinoma, Colorectal Carcinoma, Pancreatic Carcinoma, Non-small Cell Lung Carcinoma, Solid Tumors, Breast Cancer |
| Interventions | AM0010 (Biological) |
| Dates | first posted 2018-06-13, last updated 2020-03-02 |
Related Papers Related Patents Related Grants Related Experts
All trials for Melanoma All trials for Prostate Cancer All trials of AM0010
This is an Expanded Access Program (EAP) available to patients who have advanced cancers, who have failed or progressed on standard of care systemic therapy and do not qualify for ongoing clinical trials.
Sex: All, ages: 18 Years to any
* Patient is NOT eligible for other AM0010 clinical trials currently open in the region * Patient is in urgent need of therapy who fail to meet eligibility criteria for other clinical trials related to AM0010 (PEG-IL-10) can be considered for enrollment into this Expanded Access Program. * Patient has advanced cancer in indications where preliminary anti-tumor efficacy of AM0010 has been demonstrated or where AM0010 mediated immune activation is likely to benefit the patient. * Patient has failed or progressed on standard of care (SOC) systemic therapy * Patient is refusing SOC therapy